Bayer SAS, Sophia Antipolis, France.
Regul Toxicol Pharmacol. 2010 Dec;58(3 Suppl):S47-53. doi: 10.1016/j.yrtph.2010.09.013. Epub 2010 Oct 13.
As part of the safety assessment of genetically modified (GM) soybean, 2-dimensional gel electrophoresis analyses were performed with the isoxaflutole and glyphosate tolerant soybean FG72, its non-GM near-isogenic counterpart (Jack) and three commercial non-GM soybean lines. The objective was to compare the known endogenous human food allergens in seeds in the five different soybean lines in order to evaluate any potential unintended effect(s) of the genetic modification. In total, 37 protein spots representing five well known soybean food allergen groups were quantified in each genotype. Qualitatively, all the allergenic proteins were detected in the different genetic backgrounds. Quantitatively, among 37 protein spots, the levels of accumulation of three allergens were slightly lower in the GM soybean than in the non-GM counterparts. Specifically, while the levels of two of these three allergens fell within the normal range of variation observed in the four non-GM varieties, the level of the third allergen was slightly below the normal range. Overall, there was no significant increase in the level of allergens in FG72 soybean seeds. Therefore, the FG72 soybean can be considered as safe as its non-GM counterpart with regards to endogenous allergenicity. Additional research is needed to evaluate the biological variability in the levels of endogenous soybean allergens and the correlation between level of allergens and allergenic potential in order to improve the interpretation of these data in the safety assessment of GM soybean context.
作为转基因(GM)大豆安全评估的一部分,使用异噁唑草酮和草甘膦耐受大豆 FG72、其非 GM 近等基因对照(Jack)和三种商业非 GM 大豆品系进行了 2 维凝胶电泳分析。目的是比较五种不同大豆品系种子中已知的内源性人类食物过敏原,以评估遗传修饰的任何潜在意外影响。总共在每个基因型中定量了代表五种已知大豆食物过敏原组的 37 个蛋白质斑点。定性地,所有过敏原蛋白都在不同的遗传背景中被检测到。在 37 个蛋白质斑点中,定量地,在 GM 大豆中的三种过敏原的积累水平略低于非 GM 对应物。具体而言,虽然这三种过敏原中的两种的水平在四个非 GM 品种中观察到的正常变异范围内,但第三种过敏原的水平略低于正常范围。总体而言,FG72 大豆种子中过敏原的水平没有显著增加。因此,FG72 大豆可以被认为与非 GM 对应物一样安全,就内源性致敏性而言。需要进一步研究以评估内源性大豆过敏原水平的生物学变异性以及过敏原水平与过敏原潜在性之间的相关性,以便在 GM 大豆安全性评估中更好地解释这些数据。